

## Anti-Mouse CD282 (TLR2) FITC

Catalog Number :24912-50

RUO: For Research Use Only. Not for use in diagnostic procedures.

### Product Information

**Clone:** mT2.7

**Format/Conjugate:** FITC

**Concentration:** 0.5 mg/mL

**Reactivity:** Mouse

**Laser:** Blue (488nm)

**Peak Emission:** 520nm

**Peak Excitation:** 494nm

**Filter:** 530/30

**Brightness (1=dim,5=brightest):** 3

**Isotype:** Mouse IgG2a, kappa

**Formulation:** Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, pH7.2.

**Storage:** Product should be kept at 2-8°C and protected from prolonged exposure to light.

**Applications:** FC

### Description

The mT2.7 monoclonal antibody specifically reacts with mouse CD282, the Toll-like receptor 2 (TLR2). It is a type I transmembrane signaling receptor containing IL-1 receptor like intracellular domain and leucine-rich repeats (LRR) in the extracellular domain. CD282 is expressed on monocytes, macrophages, dendritic cells, and the RAW264.7 cell line and is involved distinguishing bacterial lipoproteins.

### Preparation & Storage

The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.

### Application Notes

The antibody has been analyzed for quality through the flow cytometric analysis of the relevant cell type. For flow cytometric staining, the suggested use of this reagent is ≤0.5 ug per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

### References

1.Vinnakota, K., Hu, F., Ku, M. C., Georgieva, P. B., Szulzewsky, F., Pohlmann, A., ... Kettenmann, H. (2013). Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion.;Neuro-oncology,15(11), 1457-1468.

2. Meng, G., Rutz, M., Schiemann, M., Metzger, J., Grabiec, A., Schwandner, R., ... Kirschning, C. J. (2004). Antagonistic antibody prevents toll-like receptor 2;driven lethal shock-like syndromes.;Journal of Clinical Investigation,;113(10), 1473-1481.